Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 09, 2020 09:00 ET | Source: Otonomy, Inc.

Otonomy Announces Pricing of $60.1 Million Public Offering

SAN DIEGO, July 09, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced the...
July 08, 2020 16:03 ET | Source: Otonomy, Inc.

Otonomy Announces Proposed Public Offering

SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
July 06, 2020 16:04 ET | Source: Otonomy, Inc.

Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

OTO-313 demonstrated a higher proportion of responders than placeboGiven clear signal in this proof of concept study, Otonomy plans to advance OTO-313 to full Phase 2 development in tinnitusOTO-313...
July 06, 2020 16:02 ET | Source: Otonomy, Inc.

Otonomy Provides Update on OTIVIDEX® Program

SAN DIEGO, July 06, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today provided an...
June 15, 2020 16:05 ET | Source: Otonomy, Inc.

Otonomy Provides Update on Clinical Trials and Development Programs

Results from Phase 3 trial of OTIVIDEX® in Ménière’s disease expected in first quarter of 2021Results from Phase 1/2 trial of OTO-313 in tinnitus expected in July 2020Results from Phase 1/2 trial of...
June 11, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy to Present at Raymond James 2020 Human Health Innovation Conference

SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
June 10, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy to Hold Virtual Annual Meeting of Stockholders for 2020

SAN DIEGO, June 10, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced that...
June 08, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy to Host Pipeline Program Update Conference Call and Webcast

SAN DIEGO, June 08, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it...
May 12, 2020 08:00 ET | Source: Otonomy, Inc.

Otonomy and AGTC Present Preclinical Results Supporting Selection of Product Candidate for GJB2 Gene Therapy Hearing Loss Program

SAN DIEGO, May 12, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced...
May 07, 2020 07:30 ET | Source: Otonomy, Inc.

Otonomy Reports First Quarter 2020 Financial Results and Provides Corporate Update

SAN DIEGO, May 07, 2020 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today reported...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right